Journal article
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis
Abstract
A targeted antidote for reversal of direct factor Xa (FXa) inhibitors is now available for clinical use in the United States, but it is costly and has limited availability. In a systematic review, we evaluated the safety and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) as an alternative for managing direct FXa inhibitor-related major bleeding. A systematic literature search was conducted using Medline, Embase, and the …
Authors
Piran S; Khatib R; Schulman S; Majeed A; Holbrook A; Witt DM; Wiercioch W; Schünemann HJ; Nieuwlaat R
Journal
Blood Advances, Vol. 3, No. 2, pp. 158–167
Publisher
American Society of Hematology
Publication Date
January 22, 2019
DOI
10.1182/bloodadvances.2018024133
ISSN
2473-9529